← Back to patent-cliff list
Pruvonertinib
Tier C — Watch / tradePruvonertinib
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：EGFR, EGFR exon 20 insertion mutations, EGFR T790M, EGFR 19del, EGFR L858R, EGFR PACC mutations
Indications (approved)：Non-small cell lung cancer, Drug-related adverse effects and reactions
Regional status
US
-
EU
-
China
Phase III
2023-04-08
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Pruvonertinib?
Approved indications include: Non-small cell lung cancer, Drug-related adverse effects and reactions.
When does the Pruvonertinib patent expire?
No public expiry year is available for Pruvonertinib yet; this page updates once verified.
How do I get a quote for Pruvonertinib intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-03